Summary & Overview
HCPCS J1240: Injection, dimenhydrinate, up to 50 mg
HCPCS Level II code J1240 represents the injectable form of dimenhydrinate (up to 50 mg), typically used as an antiemetic or for vertigo symptom control. Nationally, use of injectable antiemetics is relevant to acute care settings where rapid symptom control is needed, and payment policy for injectable medications affects facility and professional billing patterns.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for parenteral dimenhydrinate, payer coverage considerations, common billing modifiers used with HCPCS Level II medications, and where available, benchmarking and reimbursement context. The publication highlights practical billing and policy elements such as service line placement, typical sites of service, and common claims processing issues that affect national billing practices.
This summary equips revenue cycle managers, billing professionals, and policy analysts with concise context about the code, expected service settings, and the payer landscape relevant to administration of injectable dimenhydrinate. Data not available in the input will be noted within the full publication where applicable.
Billing Code Overview
HCPCS Level II code J1240 describes an injection of dimenhydrinate, up to 50 mg. This code represents administration of an antiemetic/antivertigo medication given by injection. Service type: injection administration of dimenhydrinate. Typical site of service: outpatient clinic, emergency department, urgent care, or other facility where parenteral medications are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an urgent care clinic or emergency department with acute nausea and vomiting related to vertigo, motion sickness, vestibular neuritis, or chemotherapeutic nausea where oral antiemetics are ineffective or contraindicated. After triage and assessment (vital signs, brief history, medication allergies, and indication for parenteral therapy), the clinician documents the indication for parenteral dimenhydrinate and the planned dose (up to 50 mg). The medication is prepared by nursing, administered by intramuscular or slow intravenous push per facility protocol, and the patient is observed for expected onset of antiemetic effect and possible adverse reactions (sedation, anticholinergic effects). If procedural sedation or additional analgesia is required, appropriate monitoring and documentation are performed. Relevant documentation includes indication, informed consent as required by site policy, route and dose, lot number and expiration, administering clinician and nurse, and patient response to medication.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure has not been modified; standard service | Use when dimenhydrinate is administered without any qualifying circumstance or modifier requirement. |
11 |